23andMe
About: 23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.
Employees: 582
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
926% more call options, than puts
Call options by funds: $1.49M | Put options by funds: $145K
0.88% less ownership
Funds ownership: 24.54% [Q3] → 23.66% (-0.88%) [Q4]
43% less funds holding
Funds holding: 115 [Q3] → 65 (-50) [Q4]
50% less funds holding in top 10
Funds holding in top 10: 4 [Q3] → 2 (-2) [Q4]
50% less capital invested
Capital invested by funds: $29M [Q3] → $14.5M (-$14.5M) [Q4]
79% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 58
94% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 47
Research analyst outlook
We haven’t received any recent analyst ratings for ME.
Financial journalist opinion
Based on 4 articles about ME published over the past 30 days
Negative
CNBC
1 week ago
23andMe special committee again rejects CEO Wojcicki's take-private offer
23andMe's special committee of independent directors on Monday rejected CEO Anne Wojcicki's proposal to take the distressed genetic testing company private. Wojcicki submitted a proposal to the committee on Sunday, offering to acquire all of the company's outstanding shares for 41 cents each.
Neutral
GlobeNewsWire
1 week ago
23andMe Special Committee Rejects Acquisition Proposal From CEO Anne Wojcicki
SUNNYVALE, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- The Special Committee of the Board of Directors of 23andMe Holding Co. (“23andMe” or the “Company”) (Nasdaq: ME) today confirmed receipt of a non-binding proposal from Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, to acquire all of the outstanding shares of capital stock of 23andMe not owned by Ms. Wojcicki and her affiliates (or any other stockholders that she invites to “roll over” their current equity ownership) for cash consideration of $0.41 per share. Ms. Wojcicki's proposal, which was included in an amended Schedule 13D filing made by Ms. Wojcicki with the Securities and Exchange Commission earlier today, represented an 84% decrease to the $2.53 per share price included in the joint non-binding proposal previously submitted by Ms. Wojcicki and her then co-bidder on February 20, 2025.
Neutral
GlobeNewsWire
2 weeks ago
YourUpdateTV Speaks with Mathew Knowles and Ruth Tennen from 23andMe to Discuss Genetic Risk Factors for Cancer
Mathew Knowles, Male Breast Cancer Survivor and Father of Beyoncé and Solange, Teams with 23andMe to Discuss the Importance of Genetic Testing in Understanding Cancer Risk Factors Mathew Knowles, Male Breast Cancer Survivor and Father of Beyoncé and Solange, Teams with 23andMe to Discuss the Importance of Genetic Testing in Understanding Cancer Risk Factors
Positive
CNBC
2 weeks ago
Anne Wojcicki has a new offer to take 23andMe private, this time for $74.7 million
23andMe CEO Anne Wojcicki and New Mountain Capital have submitted a proposal to take the company private. They are offering to buy all outstanding shares in cash for $2.53 per share, or an equity value of approximately $74.7 million.
Neutral
GlobeNewsWire
1 month ago
23andMe Launches New Genetic Report on Osteoporosis
Provides 23andMe+ Premium members with insight into their likelihood of developing osteoporosis based on thousands of genetic variants Provides 23andMe+ Premium members with insight into their likelihood of developing osteoporosis based on thousands of genetic variants
Negative
CNBC
1 month ago
23andMe is exploring strategic alternatives, looking to raise capital
23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter results that showed an 8% drop in consumer services revenue year over year.
Neutral
GlobeNewsWire
1 month ago
23andMe Special Committee Announces Exploration of Strategic Alternatives
SUNNYVALE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- The Special Committee of the Board of Directors of 23andMe Holding Co. (Nasdaq: ME) (“23andMe” or the “Company”), a leading human genetics company with a mission to help people access, understand, and benefit from the human genome, today announced that it has undertaken a process to explore strategic alternatives, including, among other alternatives, a possible sale of the company, business combination, sale of all or part of the Company's assets, licensing of assets, restructuring, or other strategic action.
Neutral
GlobeNewsWire
1 month ago
23andMe Reports Third Quarter Fiscal Year 2025 Financial Results
Company Notes Continued Concerns Regarding Liquidity and Consideration of Potential Ways to Address Operational and Financial Challenges
Neutral
PYMNTS
1 month ago
23andMe Reportedly Considers Selling Lemonaid Telehealth Unit
23andMe is reportedly considering the sale of Lemonaid Health, its telehealth operation. The consumer genetic testing kit company acquired Lemonaid in 2021 for $400 million and is now weighing a sale, per a Friday (Jan. 17) Business Insider report that cited sources familiar with the matter.
Negative
Business Insider
1 month ago
23andMe has been quietly exploring a possible sale of its telehealth business, Lemonaid
23andMe has been exploring a possible sale of its telehealth business, Business Insider has learned. The struggling health company bought virtual care startup Lemonaid in 2021 for $400 million.
Charts implemented using Lightweight Charts™